Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02323737 | Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer | completed | Phase 2 | 62 | Chinese Academy of Medical SciencesOTHER | 1 | Dec 30, 2014 | clinicaltrials |
| NCT00735696 | A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer | completed | Phase 2 | 41 | Eli Lilly and CompanyINDUSTRY | 2 | Dec 29, 2014 | clinicaltrials |
| NCT02324530 | Evaluation of Continuous Positive Airway Pressure for Tumor Motion Management in Radiotherapy | unknown | Phase 2 | 30 | Sheba Medical CenterOTHER_GOV | 1 | Dec 24, 2014 | clinicaltrials |
| NCT01761747 | Ponatinib for Squamous Cell Lung and Head and Neck Cancers | terminated | Phase 2 / Phase 3 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01763385 | Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases(TRACTS) | unknown | Phase 2 | 210 | Wu Jieping Medical FoundationOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT02013206 | A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy | completed | Phase 2 | 52 | Hoffmann-La RocheINDUSTRY | 6 | Dec 19, 2014 | clinicaltrials |
| NCT01336543 | Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | Syed JafriOTHER | 1 | Dec 18, 2014 | clinicaltrials |
| NCT02185495 | Screening for Early Lung Cancer in Shanghai, China | unknown | Phase 2 | 3,000 | Shanghai Changzheng HospitalOTHER | 1 | Dec 18, 2014 | clinicaltrials |
| NCT02319577 | GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial | unknown | Phase 2 | 80 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyOTHER | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01781988 | Personalized Therapy in Non-small Cell Lung Cancer(PTINCLC) | completed | Phase 2 | 128 | Guangzhou Medical UniversityOTHER | 1 | Dec 17, 2014 | clinicaltrials |
| NCT00160043 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer. | completed | Phase 2 | 112 | BayerINDUSTRY | 2 | Dec 16, 2014 | clinicaltrials |
| NCT00452075 | Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy | terminated | Phase 2 | 24 | Rigshospitalet, DenmarkOTHER | 1 | Dec 11, 2014 | clinicaltrials |
| NCT01664663 | Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy(PLANET) | terminated | Phase 2 | 37 | Ass. Prof. Jan NymanNETWORK | 1 | Dec 9, 2014 | clinicaltrials |
| NCT00160069 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer | completed | Phase 2 | 128 | BayerINDUSTRY | 1 | Dec 4, 2014 | clinicaltrials |
| NCT01038037 | First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer(Lung-TRIO) | terminated | Phase 2 | 23 | Vejle HospitalOTHER | 1 | Dec 4, 2014 | clinicaltrials |
| NCT00754858 | Belotecan and Cisplatin in Treating Patients With Previously Untreated, Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 42 | Yonsei UniversityOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT01498562 | Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer(DATE) | completed | Phase 2 | 160 | Yonsei UniversityOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT00240097 | Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 30 | University of Alabama at BirminghamOTHER | 1 | Nov 27, 2014 | clinicaltrials |
| NCT01784549 | Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease(CONTEST) | unknown | Phase 2 | 168 | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyOTHER | 1 | Nov 25, 2014 | clinicaltrials |
| NCT01279967 | A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma(ADAM) | unknown | Phase 2 | 70 | Barts & The London NHS TrustOTHER | 1 | Nov 20, 2014 | clinicaltrials |
| NCT00549328 | Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 1 | Nov 19, 2014 | clinicaltrials |
| NCT00726986 | Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer | terminated | Phase 2 | 18 | Afshin Dowlati, MDOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT00800202 | A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis | completed | Phase 2 | 91 | Hoffmann-La RocheINDUSTRY | 1 | Nov 19, 2014 | clinicaltrials |
| NCT01427946 | Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 47 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Nov 13, 2014 | clinicaltrials |
| NCT00531960 | A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer. | completed | Phase 2 | 124 | Hoffmann-La RocheINDUSTRY | 13 | Nov 11, 2014 | clinicaltrials |
| NCT00799240 | MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer(IMPACT) | completed | Phase 2 | 27 | University of KansasOTHER | 1 | Nov 7, 2014 | clinicaltrials |
| NCT01593995 | EGF Ointment for Erlotinib Skin Lesion | completed | Phase 2 | 52 | Dong-A University HospitalOTHER | 1 | Nov 4, 2014 | clinicaltrials |
| NCT00481078 | Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 94 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2014 | clinicaltrials |
| NCT02272127 | Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer | unknown | Phase 2 | 100 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 22, 2014 | clinicaltrials |
| NCT01844791 | An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients | completed | Phase 2 | 25 | Oncozyme Pharma Inc.INDUSTRY | 1 | Oct 21, 2014 | clinicaltrials |
| NCT02262897 | The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer | unknown | Phase 2 | 40 | Tongji UniversityOTHER | 1 | Oct 13, 2014 | clinicaltrials |
| NCT00201825 | A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients | completed | Phase 2 | 29 | Tony Bekaii-SaabOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT01473563 | A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 52 | Eli Lilly and CompanyINDUSTRY | 2 | Oct 6, 2014 | clinicaltrials |
| NCT00245063 | AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2014 | clinicaltrials |
| NCT01624051 | A Study Comparing Chemotherapy Dosing Based on Either Standard Body Surface Area or Lean Body Mass in Patients With Advanced Lung Cancer | unknown | Phase 2 | 144 | AHS Cancer Control AlbertaOTHER | 1 | Sep 30, 2014 | clinicaltrials |
| NCT00986674 | Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 140 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2014 | clinicaltrials |
| NCT00700180 | A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer. | completed | Phase 2 | 303 | Hoffmann-La RocheINDUSTRY | 16 | Sep 25, 2014 | clinicaltrials |
| NCT01424709 | Individualized Chemotherapy Based on BRCA1 and RRM1 mRNA for Advanced Non-small Cell Lung Cancer (NSCLC)(BRAVO) | unknown | Phase 2 | 120 | Tongji UniversityOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01459185 | A Feasibility Study of Oral Adjuvant Chemotherapy With S-1 | completed | Phase 2 | 55 | Tomoshi TsuchiyaOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01031225 | A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 113 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Sep 19, 2014 | clinicaltrials |
| NCT01049776 | GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line | terminated | Phase 2 | 32 | Illinois CancerCare, P.C.OTHER | 1 | Sep 19, 2014 | clinicaltrials |
| NCT01565538 | Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma | completed | Phase 2 | 123 | Si-Yu WangOTHER | 1 | Sep 15, 2014 | clinicaltrials |
| NCT02127372 | Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571 | terminated | Phase 1 / Phase 2 | 43 | Duke UniversityOTHER | 0 | Sep 15, 2014 | clinicaltrials |
| NCT00532259 | CT-011 MAb in DLBCL Patients Following ASCT | completed | Phase 2 | 72 | CureTech LtdINDUSTRY | 3 | Sep 12, 2014 | clinicaltrials |
| NCT02224547 | Risk-adapted Stereotactic Body Radiotherapy for Early Non-Small Cell Lung Cancer Using the VERO Stereotactic Body Radio Therapy System | unknown | Phase 2 | 58 | Universitair Ziekenhuis BrusselOTHER | 1 | Sep 9, 2014 | clinicaltrials |
| NCT00912392 | Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC) | completed | Phase 2 | 138 | Shandong Simcere-Medgenn Bio-pharmaceutical Co., LtdINDUSTRY | 1 | Sep 3, 2014 | clinicaltrials |
| NCT00509366 | Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer(TOP0602) | terminated | Phase 2 | 101 | Duke UniversityOTHER | 1 | Aug 28, 2014 | clinicaltrials |
| NCT00867477 | PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide | completed | Phase 2 | 163 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 28, 2014 | clinicaltrials |
| NCT00118144 | Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2014 | clinicaltrials |
Data updated 24 days agoSource updated Dec 30, 2014source: clinicaltrials